New Immunotherapy Clinical Trial for Unresectable Meso
The National Cancer Institute is currently recruiting malignant pleural or peritoneal mesothelioma patients for a phase I clinical trial aimed at patients unable to undergo surgery and who have not responded to standard first-line treatments for mesothelioma.
LMB-100 is an immunotoxin drug that targets mesothelin, the cancerous protein expressed in the cells of mesothelioma patients. Although LMB-100 has shown some effectiveness in previous studies, over time, patients grew resistant to it. In this study, researchers are hoping to see if injecting LMB-100 directly into a tumor and combining treatment with the immunotherapy drug, ipilimumab (brand name Yervoy), will have greater therapeutic effects.
For more study information, including eligibility criteria, visit:
